Eli Lilly and Company / Protomer Technologies

Type 2 Diabetes (Glucose-Responsive Insulin)

7 US cases/yr · $22.0B U.S. insulin market 2021 · >$1B Total deal value (upfront + future development & commercial milestones)

Disease Overview

The Lilly-Protomer acquisition targets type 2 diabetes (T2D) via glucose-responsive 'smart' insulin technology. T2D affects approximately 37 million U.S. adults (11.3% prevalence) with another 96 million pre-diabetic. Insulin-treated diabetes accounts for approximately 7-8 million U.S. patients across T1D (~1.6 million) and insulin-dependent T2D (~5-6 million). Hypoglycemia is the principal acute safety concern in insulin-treated diabetes, with an estimated 100,000+ U.S. emergency department visits annually attributable to severe hypoglycemia. Glucose-responsive (smart) insulin is a long-pursued holy grail in diabetes therapeutics — an insulin molecule whose activity is automatically modulated by ambient glucose concentration, theoretically eliminating both hypoglycemia and hyperglycemia. Protomer's peptide and protein engineering platform uses synthetic glucose-binding domains conjugated to insulin to create molecules that increase activity in hyperglycemic states and decrease activity in normoglycemic/hypoglycemic states. Lilly previously held a 14% equity stake in Protomer dating to a 2019 Series A and triggered the acquisition based on positive preclinical proof-of-concept data. The U.S. insulin market generates approximately $20-25B in annual revenue across rapid-acting (Humalog/lispro, NovoLog/aspart, Fiasp), long-acting (Lantus/glargine, Tresiba/degludec, Toujeo, Basaglar, Semglee biosimilar), and pre-mix categories.

Competitive Landscape

The diabetes therapeutics competitive landscape is at the most disruptive moment in its history. Incretin-class agents include semaglutide (Ozempic/Wegovy/Rybelsus, Novo Nordisk, $20B+ revenue), tirzepatide (Mounjaro/Zepbound, Lilly, dual GIP/GLP-1 agonist, FDA approved 2022/2023), liraglutide (Victoza/Saxenda, Novo, $1B+ revenue, generic 2024), dulaglutide (Trulicity, Lilly, declining), exenatide (Byetta/Bydureon, AstraZeneca/Amylin), and lixisenatide (Adlyxin, Sanofi). Insulin franchises are dominated by Lilly (Humalog/lispro, Trulicity-pivot), Novo Nordisk (NovoLog/aspart, Tresiba/degludec, Fiasp), and Sanofi (Lantus/glargine, Toujeo, Soliqua). Glucose-responsive insulin competitors include Merck's MK-2640 (discontinued 2017 after Phase 1) and Novo Nordisk's NN1845 (preclinical). Smart insulin academic programs include MIT/Daniel Anderson's MK-2640-class glucose-responsive analogs and the Tang lab's polymer-based responsive insulins. Other next-generation insulin programs include once-weekly basal insulin icodec (Awiqli, Novo, FDA approved 2024) and Lilly's basal insulin Fc (BIF) once-weekly (Phase 3). Protomer's peptide engineering platform is differentiated by tunable glucose-binding domain chemistry that may enable not only smart insulin but glucose-responsive GLP-1 and GIP analogs as Lilly extends its incretin portfolio.